Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits

Podcast: Connected With Latham · Latham & Watkins

Opublikowano: 2025-11-24

Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help uncovering strategic benefits and opportunities. In this episode of Connected With Latham, Eliza Biedziak, Managing Director at Ernst & Young LLP, joins Washington, D.C. partner Chris Schott and associate Danny Machado to explore how these assessments are conducted, the compliance benefits they offer, and the strategic insights they can provide. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox. This podcast is provided as...